Quick Answer
Spyre Therapeutics, Inc. reported Stockholders Equity of $715.24 million for the year ending 2025.
- Spyre Therapeutics, Inc. showed an increase of +38.1% in Stockholders Equity from 2024 to 2025.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $116.29 million | Q2 2019: $99.62 million | Q3 2019: $79.80 million | Q1 2020: $42.81 million | Q2 2020: $152.26 million | Q3 2020: $136.27 million | Q1 2021: $123.76 million | Q2 2021: $119.02 million | Q3 2021: $102.08 million | Q1 2022: $61.66 million | Q2 2022: $84.16 million | Q3 2022: $67.56 million | Q1 2023: $33.65 million | Q2 2023: -$207.37 million | Q3 2023: -$245.40 million | Q1 2024: $152.27 million | Q2 2024: $374.39 million | Q3 2024: $327.39 million | Q1 2025: $482.61 million | Q2 2025: $455.77 million | Q3 2025: $455.10 million.
- Over the full 13 years of available data (2013 to 2025), Spyre Therapeutics, Inc.'s Stockholders Equity has grown by 56,285.1%.
- Historical annual values: Fiscal year 2025: $715.24 million | Fiscal year 2024: $517.80 million | Fiscal year 2023: $184.02 million | Fiscal year 2022: $50.31 million | Fiscal year 2021: $83.94 million | Fiscal year 2020: $139.83 million | Fiscal year 2019: $60.08 million | Fiscal year 2018: $67.43 million | Fiscal year 2017: $50.34 million | Fiscal year 2016: $62.97 million | Fiscal year 2015: -$22.21 million | Fiscal year 2014: -$11.47 million | Fiscal year 2013: -$1.27 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: